The meta-analysis showed (Fig. 7) that Immune checkpoint inhibitors versus chemotherapy had prolonged the NSCLC patients with KRAS mutation for the OS (HR, 0.61; 95% CI, 0.39–0.94). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.